| Document |
Document Title |
|
WO/2015/135927A1 |
The invention relates to 2,4,6-octatrienoic acid derivative compounds having general formula (I) (CH3-CH=CH-CH=CH-CH=CH-CO-O-)n-R (I) consisting of esters wherein n = 1, 2, 3 and wherein R is selected from alkyl, aryl or cycloalkyl of a ...
|
|
WO/2015/133928A1 |
The invention relates to antiviral agents and specifically to synthetic biologically-active derivatives, and can be used in the pharmaceutical industry, in medicine, in plant husbandry and in biotechnology. An antiviral agent which is...
|
|
WO/2015/111640A1 |
The present invention addresses the problem of providing: a compound that is capable of forming a composition having good shelf life such that even if the compound is stored long term in a state of being mixed with a base-reactive compou...
|
|
WO/2015/112093A2 |
The present invention relates to peptidomimetics of the formula (I) or (I)c wherein L1, L2, L3, R1, R2, R3, R4, R5, R6, n, m, Q, X, Ζ1 and Z2 are defined as mentioned in the description and to salts and solvates of each of these compoun...
|
|
WO/2015/094938A1 |
Laminated articles are provided including a porous fibrous nonwoven matrix and guanidine-functionalized metal silicate particles enmeshed within the porous fibrous nonwoven matrix. The laminated articles further include a first substrate...
|
|
WO/2015/087857A1 |
Provided is an aryl amidine compound that has excellent bactericidal activity, is highly safe, can be synthesized in an industrially advantageous manner, and is represented by formula (II) or the like. Also provided is a bactericidal age...
|
|
WO/2015/089137A1 |
The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin inclu...
|
|
WO/2015/083331A1 |
Provided are a photobase generator having higher sensitivity to light than do conventional photobase generators, and a photosensitive resin composition containing the photobase generator. The present invention is a photobase generator ch...
|
|
WO/2015/078774A1 |
The invention relates to the production of an ionic liquid comprising a chalcogenide anion from an ionic liquid comprising a carbonate anion using anion exchange as well as to the use of the obtained chalcogenide compond comprising an or...
|
|
WO/2015/065243A1 |
The claimed invention relates to the field of biologically active compounds and concerns 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]
triazinide L-arginine dihydrate, which exhibits an antiviral effect and is intended for...
|
|
WO/2015/026687A1 |
The present invention provides curable compositions comprising non-tin metal accelerators that accelerate the condensation curing of moisture-curable silicones/non-silicones. In particular, the present invention provides an accelerator c...
|
|
WO/2015/006875A1 |
This invention relates to an improved process of making compounds of Formula (I) and synthetic intermediates thereof. (I) In particular, the invention relates to an improved process to prepare N-(2-aminophenyl)-4- ((pyrimidin-2-ylamino)m...
|
|
WO/2014/208632A1 |
The present invention addresses the problem of providing: a base generator which has high solubility in widely used organic solvents, can be dissolved directly in a base-reactive compound such as an epoxy compound, has both high heat res...
|
|
WO/2014/204763A1 |
A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino ...
|
|
WO/2014/176636A9 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2014/195961A1 |
The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods ...
|
|
WO/2014/189246A1 |
The present invention provides a novel use of an N1-cyclic amine-N5-substituted biguanide derivative for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivative according to the p...
|
|
WO/2014/161412A1 |
Disclose in the invention are a tricyclic quinolone derivative having a novel structure with a peripheral group at position C10 being substituted by non-alkaline substituents or salts and hydrates thereof. Such compounds have been proven...
|
|
WO/2014/152431A1 |
Provided herein are stabilized radioiodinated and astatinated compounds, and to methods for their preparation.
|
|
WO/2014/139572A1 |
The present invention relates to an improved process for making anagrelide of formula (1), or an acid addition salt thereof, including any hydrated or solvated form thereof, comprising reacting a compound of formula (3), or an acid addit...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/142219A1 |
[Problem] To provide a compound useful as a drug for preventing and/or treating kidney disease. [Solution] The inventors studied compounds having trypsin-inhibiting activity, confirmed that guanidinobenzoic acid ester compounds have tryp...
|
|
WO/2014/124796A1 |
The present invention relates to a two‑ply, dielectric layer for a thin‑layer capacitor, characterized in that a) the bottom, first ply (4) comprises a self‑assembled monolayer containing phosphorus oxo compounds and b) the top, se...
|
|
WO/2014/123364A1 |
The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceut...
|
|
WO/2014/121648A1 |
The present invention discloses a synthesis method for creatine. In a case of vacuum, carbamide and aqueous solution of sodium sarcosinate are mixed and heated. After drying, acid is added to adjust a pH value, and thermal reaction is pe...
|
|
WO/2014/111113A1 |
The present invention relates to compounds of formula (I) and, in particular, drugs containing at least one compound of formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states, in the cause...
|
|
WO/2014/093231A2 |
The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infecti...
|
|
WO/2014/088807A1 |
Guanidine-functionalized particles and methods of making and using such particles.
|
|
WO/2014/082592A1 |
Provided are a compound as represented by formula Ia, or pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof. As a neuraminidase inhibitor prodrug, the compound can improve the half-life in vivo of...
|
|
WO/2014/082594A1 |
Provided are a compound shown in formula 1 or a purpose of a prodrug thereof in preparing medicines for treating and/or preventing infection of Tamiflu-resistant influenza virus strains. The Tamiflu-resistant influenza virus strains is p...
|
|
WO/2014/069555A1 |
Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ing...
|
|
WO/2014/064094A1 |
The present invention relates t oazines of formula (I) wherein the variables are defined according to the description, processes and intermediated for preparing them, compositions comprising them and their use as herbicides, i.e. for con...
|
|
WO/2014/061734A1 |
The present application addresses the problem of providing a novel salty taste-enhancing agent and a manufacturing method therefor, as well as a method for enhancing the salty taste of a food or drink. As a means for solving said problem...
|
|
WO/2014/019855A1 |
The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group...
|
|
WO/2014/016766A1 |
The present invention is directed to guanidine derivatives as inhibitors of transient receptor potential canonical channels (TRPC channels), in particular TRPC3 and/or TRPC6 and/or TRPC7 activity, more particularly TRPC6 activity. Also p...
|
|
WO/2014/015054A1 |
Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods fo...
|
|
WO/2014/011814A1 |
Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or doc...
|
|
WO/2014/007326A1 |
The purpose of the present invention is to provide a process for producing nafamostat mesylate without via nafamostat bicarbonate and while avoiding inclusion of sodium mesylate. The process for producing nafamostat mesylate comprises (1...
|
|
WO/2013/188452A1 |
Presented herein inter alia are novel compounds and methods of using the same for the treatment of cancers.
|
|
WO/2013/178065A1 |
Disclosed are an amino acid copper complex with the effects of preventing alopecia, growing hair and protecting skin, a preparation method and application. The amino acid copper complex is obtained by complexing divalent copper ions with...
|
|
WO/2013/138666A1 |
Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC i...
|
|
WO/2013/138665A1 |
Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC i...
|
|
WO/2013/117846A1 |
The invention relates to a cosmetic composition including at least one compound of formula (I), used alone or as part of a mixture, or one of the salts, hydrates, acetals, or hemiacetals thereof, where Y is an OR, NRR', or R group with R...
|
|
WO/2013/060889A1 |
The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.
|
|
WO/2013/053726A1 |
Provided herein are phenyl-guanidine derivatives for the inhibition of Rac1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumour...
|
|
WO/2013/047372A1 |
[Problem] To provide a method for producing a polypeptide fragment with high efficiency, which is suitable for an NCL method. [Solution] A production method comprising: a step of reacting a polypeptide which comprises a first polypeptide...
|
|
WO/2013/042082A1 |
The present invention relates to novel compounds having the following formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, for the...
|
|
WO/2013/039187A1 |
[Problem] To provide a compound useful as a renal disease preventive and/or therapeutic agent. [Solution] The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoi...
|
|
WO/2013/034756A1 |
The present invention relates to a compound of formula (I), wherein R1 and R2 are independently selected from (a) C1 to C6 alkyl; C2 to C6 alkenyl; C2 to C6 alkynyl; substituted or unsubstituted heterocycloalkyl or cycloalkyl, substituen...
|
|
WO/2013/035102A1 |
The invention relates to an improved process for the preparation of highly pure imatinib base (99.99% HPLC purity) of formula (I) and the pharmaceutically acceptable acid addition salts thereof. This invention also relates to processes f...
|
